Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, Board Director of Levicept and Chair of Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
Read this article highlighting our viral immunotherapy approach and promising clinical results across multiple solid tumors.
It covers our positive phase 3 data in prostate cancer and our plans to file a BLA for CAN-2409 in late 2026.
https://www.nature.com/articles/d43747-025-00101-6
$CADL
#TBT to last month when Candel was honored with the 2025 Scrip Award for Best Oncology R&D Advance!
This recognition celebrates our successful phase 3 study of CAN-2409 in localized prostate cancer.
Thank you to @Citeline for this honor.
https://citeline.com/en/awards/scripawards
$CADL
Next week, our executive team will be in San Francisco for the J.P. Morgan Healthcare Conference. We look forward to connecting with industry leaders and the investor community.
Hope to see you there!
#JPM2026 #Healthcare #Biotech $CADL
PharmaVoice’s Crystal Ball: Market and policy forces shaping the industry | PharmaVoice
